시장보고서

상품코드

1841961

리포솜 독소루비신 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 09월 | 리서치사:

Grand View Research | 페이지 정보: 영문 125 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포솜 독소루비신 시장 요약

전 세계 리포솜 독소루비신 시장 규모는 2024년에 13억 1,000만 달러로 추정되며 2033년에는 23억 8,000만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 7.04%의 CAGR로 성장할 것으로 예상됩니다.

암 환자 수, 특히 유방암 환자 수의 증가가 리포솜 독소루비신 시장을 활성화시키고 있습니다.

혁신적인 약물 제제를 위한 나노기술의 발전은 이 시장을 더욱 강화할 것입니다. 리포솜 제제는 기존 제제보다 효과가 높고 부작용이 적어 암 치료에 혁명을 가져올 것입니다. 또한, 전달과 안정성을 개선하고 새로운 치료 용도를 개척하기 위한 지속적인 연구가 시장의 급격한 성장을 견인하고 있습니다.

리포솜 독소루비신은 부작용이 적은 표적 화학요법을 제공하여 선호되는 치료법으로, 암 진단 건수가 증가함에 따라 리포솜 독소루비신 시장이 성장하고 있습니다. 예를 들어, 국제암연구소(IARC)는 2022년 신규 암 환자 수를 2,000만 명으로 추정하고 있으며, 2050년에는 3,500만 명으로 증가할 것으로 예측하고 있어 전 세계적인 암 부담의 증가가 두드러지고 있습니다.

리포솜 독소루비신 약물전달에 있어 나노기술의 발전은 첨단 리포솜 독소루비신 제제에 대한 수요를 증가시켜 시장을 주도하고 있습니다. 예를 들어, ACS Publications지에 게재된 연구에 따르면, 나노보울 탑재 리포솜 DOX(DOX@NbLipo)는 혈장 단백질과 혈류 전단력에 대한 내성이 높아 표적 조직으로의 약물전달에 있어 약물 누출을 최소화했습니다. 그 결과, DOX@NbLipo는 다른 대조군에 비해 생쥐의 생존 기간을 연장시켰습니다(최대 50일). 또한 DOX@NbLipo 치료로 생쥐의 수명이 108.3% 연장되었습니다.

리포솜 독소루비신의 다양한 적응증에 대한 지속적인 연구가 시장을 주도하고 있습니다. 예를 들어, European Journal of Cancer에 게재된 연구에 따르면, TLD-1(신규 리포솜 독소루비신)은 진행성 고형암 환자에서 기존 독소루비신 제제 대비 높은 효능을 보였습니다.

시장 점유율 분석 : 지역별(2024년·2033년)
지역별 대시보드
시장 규모 예측과 동향 분석(2021-2033년)
북미
- 국가별(2021-2033년)
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

참여자 개요
기업의 시장 포지션 분석
기업 분류
전략 매핑
기업 개요/상장 기업
- Sun Pharmaceutical Industries Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Cipla
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Lupin
- Cadila Pharmaceuticals
- SRS Life Sciences
- GSK plc
- Pfizer Inc.
- Sanofi
- Sigma-Aldrich Co.

KSM 25.11.05

Liposomal Doxorubicin Market Summary

The global liposomal doxorubicin market size was estimated at USD 1.31 billion in 2024 and is projected to reach USD 2.38 billion by 2033, growing at a CAGR of 7.04% from 2025 to 2033. The rising number of cancer cases, particularly breast cancer, fuels the liposomal doxorubicin market.

Advancements in nanotech for innovative drug formulations further strengthen this market. Liposomal delivery revolutionizes cancer treatment by offering increased effectiveness and lower side effects than traditional forms. Furthermore, ongoing research to improve delivery and stability and explore new therapeutic applications propels the market's rapid growth.

Rising cancer diagnoses propel the liposomal doxorubicin market, as it offers targeted chemotherapy with reduced side effects, making it a preferred treatment. For instance, the International Agency for Research on Cancer (IARC) estimates 20 million new cancer cases in 2022, projected to rise to 35 million by 2050, highlighting a growing global cancer burden.

Nano-technological advancements in the drug delivery of liposomal doxorubicin are driving the market by increasing the demand for advanced liposomal doxorubicin formulations. For instance, according to a study published in ACS Publications, Nanobowl-supported liposomal DOX (DOX@NbLipo) is more resistant towards the plasma proteins and blood flow shear force that resulted in minimal drug leakage in the drug delivery at targeted tissue. The study showed that DOX@NbLipo led to prolonged survival of the mice (up to 50 days) compared to other controls. The DOX@NbLipo treatment also led to the biggest increase in the lifespan of the mice by 108.3%.

Ongoing research on liposomal doxorubicin for different indications is propelling the market. For instance, a study published in the European Journal of Cancer demonstrated the higher efficacy of TLD-1 (Novel liposomal doxorubicin) as compared to conventional doxorubicin formulations in patients with advanced solid tumors.

Global Liposomal Doxorubicin Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liposomal doxorubicin market report based on product, application, distribution channel, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Doxil/Caelyx
Lipodox
Myocet
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Breast Cancer
Ovarian Cancer
AIDS-related Kaposi's Sarcoma
Multiple Myeloma
Other Solid Tumors
Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis

Chapter 4. Liposomal Doxorubicin Market: Product Business Analysis

4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Doxil/Caelyx
- 4.4.1. Doxil/Caelyx Market, 2021 - 2033 (USD Million)
4.5. Lipodox
- 4.5.1. Lipodox Market, 2021 - 2033 (USD Million)
4.6. Myocet
- 4.6.1. Myocet Market, 2021 - 2033 (USD Million)
4.7. Others
- 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Liposomal Doxorubicin Market: Application Business Analysis

5.1. Application Market Share, 2024 & 2033
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Breast Cancer
- 5.4.1. Breast Cancer Market, 2021 - 2033 (USD Million)
5.5. Ovarian Cancer
- 5.5.1. Ovarian Cancer Market, 2021 - 2033 (USD Million)
5.6. AIDS related Kaposi's Sarcoma
- 5.6.1. AIDS related Kaposi's Sarcoma Market, 2021 - 2033 (USD Million)
5.7. Multiple Myeloma
- 5.7.1. Multiple Myeloma Market, 2021 - 2033 (USD Million)
5.8. Other Solid Tumors
- 5.8.1. Other Solid Tumors Market, 2021 - 2033 (USD Million)

Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Business Analysis

6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
7.4. North America
- 7.4.1. North America Liposomal Doxorubicin Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Mexico Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
- 7.5.1. Europe Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. UK Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Germany Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. France Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Italy Liposomal Doxorubici Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Spain Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Denmark Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Sweden Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Norway Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
  - 7.6.3.1. China Liposomal DoxorubicinMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. India Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Australia Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. South Korea Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Thailand Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Liposomal DoxorubicinMarket Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. China Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. South Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Saudi Arabia Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. UAE Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Kuwait Liposomal Doxorubicin Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Sun Pharmaceutical Industries Ltd.
  - 8.5.1.1. Company Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Johnson & Johnson
  - 8.5.2.1. Company Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Merck & Co., Inc.
  - 8.5.3.1. Company Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Cipla
  - 8.5.4.1. Company Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  - 8.5.5.1. Company Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. Lupin
  - 8.5.6.1. Company Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Cadila Pharmaceuticals
  - 8.5.7.1. Company Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. SRS Life Sciences
  - 8.5.8.1. Company Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. GSK plc
  - 8.5.9.1. Company Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Pfizer Inc.
  - 8.5.10.1. Company Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives
- 8.5.11. Sanofi
  - 8.5.11.1. Company Overview
  - 8.5.11.2. Financial Performance
  - 8.5.11.3. Product Benchmarking
  - 8.5.11.4. Strategic Initiatives
- 8.5.12. Sigma-Aldrich Co.
  - 8.5.12.1. Company Overview
  - 8.5.12.2. Financial Performance
  - 8.5.12.3. Product Benchmarking
  - 8.5.12.4. Strategic Initiatives

리포솜 독소루비신 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

리포솜 독소루비신 시장 요약

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 리포솜 독소루비신 시장 : 변수, 동향, 범위

제4장 리포솜 독소루비신 시장 : 제품별 비즈니스 분석

제5장 리포솜 독소루비신 시장 : 용도별 비즈니스 분석

제6장 리포솜 독소루비신 시장 : 유통 채널별 비즈니스 분석

제7장 리포솜 독소루비신 시장 : 지역별 추정·동향 분석